Shigenori E. Nagai

797 citations

31 papers · 441 indexed · h-index 13

Co-authors: Kenichi Inoue Hirofumi Mukai Masafumi Kurosumi Hiroyuki Takei Yuji Hayashi Takashi Yoshida Toshio Tabei Hiroji Iwata
Topics: Cancer Treatment and Pharmacology (16 papers)Breast Cancer Treatment Studies (14 papers)HER2/EGFR in Cancer Research (10 papers)
Cited by: Cancer Research Oncology Biomaterials
Journals: Journal of Clinical Oncology Scientific Reports British Journal of Cancer
Partner nations: Japan United States South Africa

In The Last Decade

Shigenori E. Nagai

28 papers receiving 435 citations

Peers

Countries citing papers authored by Shigenori E. Nagai

Since Specialization

Citations

This map shows the geographic impact of Shigenori E. Nagai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shigenori E. Nagai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shigenori E. Nagai more than expected).

Fields of papers citing papers by Shigenori E. Nagai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shigenori E. Nagai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shigenori E. Nagai. The network helps show where Shigenori E. Nagai may publish in the future.

Co-authorship network of co-authors of Shigenori E. Nagai

This figure shows the co-authorship network connecting the top 25 collaborators of Shigenori E. Nagai. A scholar is included among the top collaborators of Shigenori E. Nagai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shigenori E. Nagai. Shigenori E. Nagai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment 2024 ·Breast Cancer ·Yutaka Yamamoto,Chikako Yamauchi,Tatsuya Toyama,Shigenori E. Nagai,Takehiko Sakai,Goro Kutomi,Michio Yoshimura,Masaaki Kawai,Shoichiro Ohtani,Kazunori Kubota,Kazutaka Nakashima,Naoko Honma,Masayuki Yoshida,Eriko Tokunaga,Naruto Taira,Hiroji Iwata,Shigehira Saji	2
2	Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study 2024 ·Breast Cancer ·Tetsuhiro Yoshinami,Shigenori E. Nagai,Masaya Hattori,Takuho Okamura,Kenichi Watanabe,Takahiro Nakayama,Hiroko Masuda,Michiko Tsuneizumi,Daisuke Takabatake,Michiko Harao,Hiroshi Yoshino,(unknown),Hiroyuki Yasojima,(unknown),Madoka Iwase,Miki Yamaguchi,Takafumi Sangai,Nobuyoshi Kosaka,(unknown),Norikazu Masuda	2
3	Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial 2021 ·Breast Cancer Research and Treatment ·Norikazu Masuda,Hiroko Bando,Takashi Yamanaka,Takayuki Kadoya,Masato Takahashi,Shigenori E. Nagai,Shoichiro Ohtani,Tomoyuki Aruga,Eiji Suzuki,Yuichiro Kikawa,Hiroyuki Yasojima,(unknown),Hiroshi Ishiguro,Hidetaka Kawabata,Satoshi Morita,Hironori Haga,Tatsuki R. Kataoka,Ryuji Uozumi,Shinji Ohno,Masakazu Toi	12
4	Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer 2021 ·Scientific Reports ·(unknown),(unknown),Shigenori E. Nagai,Yasuhito Kobayashi,(unknown),(unknown),Ken Takai,Kenichi Inoue,Hiroshi Matsumoto,(unknown),Masami Suganuma	4
5	The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study 2020 ·Breast Cancer Research and Treatment ·Masato Takahashi,Shoichiro Ohtani,Shigenori E. Nagai,Seiki Takashima,Miki Yamaguchi,Michiko Tsuneizumi,Yoshifumi Komoike,Tomofumi Osako,Yoshinori Ito,Masahiko Ikeda,Kazushige Ishida,Takahiro Nakayama,Tsutomu Takashima,T. Asakawa,Sho Matsumoto,Daisuke Shimizu,Norikazu Masuda	7
6	163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22) 2020 ·Annals of Oncology ·Hiroko Bando,Norikazu Masuda,Takashi Yamanaka,Takayuki Kadoya,(unknown),Shigenori E. Nagai,Shoichiro Ohtani,Tomoyuki Aruga,Eiji Suzuki,Yuichiro Kikawa,Hiroyuki Yasojima,Haruo Kasai,Hiroshi Ishiguro,Hidetaka Kawabata,Satoshi Morita,Hironori Haga,Tatsuki R. Kataoka,Ryuji Uozumi,Shinji Ohno,Masakazu Toi	1
7	Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition 2020 ·Breast Cancer ·Tetsuhiro Yoshinami,Kei Koizumi,Shigenori E. Nagai,Tatsuya Toyama,Hiroji Iwata	3
8	Relation between dexamethasone (DEX) usage, preventive trimetprim/sulfametoxazole (ST), and pneumocystis pneumonia (PCP) for patients with breast cancer receiving dose-dense AC followed by dose-dense paclitaxel (ddAC-ddP): Preplanned analysis of WJOG9016B. 2019 ·Journal of Clinical Oncology ·Koji Matsumoto,(unknown),Yukinori Ozaki,Manabu Futamura,(unknown),Junji Tsurutani,Shigeru Imoto,(unknown),Shinya Tokunaga,Kenjiro Aogi,Kenichi Yoshimura,(unknown),Yasuaki Sagara,(unknown),Shigenori E. Nagai,Toshimi Takano,(unknown)	3
9	A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients 2019 ·British Journal of Cancer ·Yasuhiro Fujiwara,Hirofumi Mukai,Toshiaki Saeki,Jungsil Ro,Yung‐Chang Lin,Shigenori E. Nagai,Keun Seok Lee,Junichiro Watanabe,Shoichiro Ohtani,Sung Bae Kim,Katsumasa Kuroi,Koichiro Tsugawa,Yutaka Tokuda,Hiroji Iwata,Winnie Yeo,Youngsen Yang,Yoshihiro Nambu	96
10	TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study 2019 ·Investigational New Drugs ·Kenichi Inoue,Shigenori E. Nagai,Tsuyoshi Saito,Takashi Sakurai,Kei Kimizuka,Hirofumi Yamada,Toru Kuroda,Satoshi Hata,Yasuo Yamazaki,(unknown),(unknown),(unknown)	1
11	A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients 2017 ·Annals of Oncology ·Toshiaki Saeki,Hirofumi Mukai,Jungsil Ro,(unknown),Yasuhiro Fujiwara,Shigenori E. Nagai,(unknown),Junichiro Watanabe,Shoichiro Ohtani,S.B. Kim,Katsumasa Kuroi,Koichiro Tsugawa,Yutaka Tokuda,Hiroji Iwata,Y.H. Park,Youngsen Yang,Yoshihiro Nambu	7
12	RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer 2017 ·Clinical Breast Cancer ·José Baselga,Claudio Zamagni,Patricia Gómez,Begoña Bermejo,Shigenori E. Nagai,Bohuslav Melichar,Arlene Chan,László Mangel,Jonas Bergh,Frederico Costa,Henry Gómez,William J. Gradishar,Clifford A. Hudis,Bernardo L. Rapoport,Henri Roché,Patricia Maeda,Liping Huang,Gerold Meinhardt,Joshua Zhang,Lee S. Schwartzberg	37
13	Cross-cultural comparison of breast cancer patients’ Quality of Life in the Netherlands and Japan 2017 ·Breast Cancer Research and Treatment ·Maarten J. Fischer,Kenichi Inoue,Ayako Matsuda,Judith R. Kroep,Shigenori E. Nagai,(unknown),(unknown),Nir I. Weijl,(unknown),(unknown),J.W.R. Nortier,Hein Putter,Kazue Yamaoka,Kaoru Kubota,Kunihiko Kobayashi,Ad A. Kaptein	20
14	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition 2016 ·Breast Cancer ·Tomohiko Aihara,Tatsuya Toyama,Masato Takahashi,Yutaka Yamamoto,Fumikata Hara,Hiromitsu Akabane,Tomomi Fujisawa,Takashi Ishikawa,Shigenori E. Nagai,Rikiya Nakamura,Junji Tsurutani,Yoshinori Ito,Hirofumi Mukai	68
15	We’re in this together: Patients’, caregivers’ and health care providers’ illness perceptions about non-small-cell lung cancer (NSCLC) 2015 ·Lung Cancer ·Ad A. Kaptein,Kunihiko Kobayashi,Ayako Matsuda,Kaoru Kubota,Shigenori E. Nagai,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Kenichi Inoue,(unknown),Christian Taube,Judith R. Kroep,Maarten J. Fischer	6
16	Impact of immediate breast reconstruction on postoperative adjuvant chemotherapy: a single center study 2013 ·Breast Cancer ·Atsumori Hamahata,(unknown),Hiroyuki Takei,Takashi Saitou,Yuji Hayashi,Hiroshi Matsumoto,Shigenori E. Nagai,Kenichi Inoue,Masafumi Kurosumi,Takashi Yamaki,Hiroyuki Sakurai	17
17	Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer 2012 ·Oncology Letters ·Yuji Hayashi,Hiroyuki Takei,(unknown),(unknown),Akihiro Ichikawa,Naoki Kobayashi,Masafumi Kurosumi,Kenichi Inoue,Takashi Yoshida,Shigenori E. Nagai,(unknown),Toshio Tabei,Jun Horiguchi,Izumi Takeyoshi	56
18	Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages? 2010 ·Breast Cancer ·Hiroyuki Takei,Masafumi Kurosumi,Takashi Yoshida,Yuji Hayashi,Toru Higuchi,(unknown),Jun Ninomiya,(unknown),Kenichi Inoue,Shigenori E. Nagai,Toshio Tabei	18
19	Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies 2009 ·Breast Cancer ·Hiroyuki Takei,Masafumi Kurosumi,Takashi Yoshida,Yuko Ishikawa,Yuji Hayashi,Jun Ninomiya,(unknown),(unknown),Kenichi Inoue,Shigenori E. Nagai,Yoshihiro Saito,Tomoko Kazumoto,Jun‐ichi Saitoh,Toshio Tabei	16
20	[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline]. 1999 ·PubMed ·Shigenori E. Nagai,(unknown),Katsumasa Kuroi,Kazuo Hayashi,T. Tominaga	3

About Shigenori E. Nagai

Shigenori E. Nagai is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 31 papers that have together received 441 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (16 papers), Breast Cancer Treatment Studies (14 papers) and HER2/EGFR in Cancer Research (10 papers). The work is most often cited by research in Cancer Research (194 citations), Oncology (202 citations) and Biomaterials (86 citations). Shigenori E. Nagai has collaborated with scholars based in Japan, United States and South Africa. Frequent co-authors include Kenichi Inoue, Hirofumi Mukai, Masafumi Kurosumi, Hiroyuki Takei, Yuji Hayashi, Takashi Yoshida, Toshio Tabei, Hiroji Iwata, Yutaka Yamamoto and Shoichiro Ohtani. Their work appears in journals such as Journal of Clinical Oncology, Scientific Reports and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact